Skip to main content

Advertisement

Log in

Escherichia coli O157: What every internist and gastroenterologist should know

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Infections with Escherichia coli O157:H7 have gained media attention in recent years because of cases associated with unusual sources (eg, produce and swimming pools). Although most adults recover without sequelae, children and the elderly are more likely to develop complications (eg, hemolytic uremic syndrome and death). The diagnosis typically has been made by culture; however, newer handheld immunoassays and polymerase chain reaction technology have led to more rapid detection of this important pathogen in stools, food, and water. Treatment is largely supportive; nonetheless, new methods to neutralize or bind toxin, such as probiotics, monoclonal antibodies, and recombinant bacteria, are showing promise to treat patients infected with E. coli O157:H7. The role of antibiotics in relation to this condition remains unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gasser C, Gautier E, Steck A, et al.: Hämlytisch-urämische syndrom: bilaterale nierenrindennekrosen bei akuten erworbenen hämolytischen anämien. Schweiz Med Wochenschr 1955, 85:905–909.

    PubMed  CAS  Google Scholar 

  2. Karmali MA, Steele BT, Petric M, Lim C: Sporadic cases of hemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983, 65:619–620.

    Article  Google Scholar 

  3. Mead PS, Slustsker L, Dietz V, et al.: Food-related illness in the United States. Emerg Infect Dis 1999, 607–625.

  4. Tarr PI, Gordon CA, Chandler WL: Shiga toxin producing Escherichia coli and haemolytic syndrome. Lancet 2005, 365:1073–1086.

    PubMed  CAS  Google Scholar 

  5. Jay MT, Garrett V, Mohle-Boetani JC, et al.: A multistate outbreak of Escherichia coli O157:H7 infection linked to consumption of beef tacos at a fast-food restaurant chain. Clin Infect Dis 2004, 39:1–7.

    Article  PubMed  Google Scholar 

  6. Bell BP, Goldoft M, Griffin PM, et al.: A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers: the Washington experience. JAMA 1994, 272:1349–1353.

    Article  PubMed  CAS  Google Scholar 

  7. Hillborn ED, Mermin JH, Mshar PA, et al.: A multistate outbreak of mesclun lettuce. Arch Intern Med 1999, 159:1758–1764.

    Article  Google Scholar 

  8. Cody SH, Glynn MK, Farrar JA, et al.: An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann Intern Med 1999, 130:202–209.

    PubMed  CAS  Google Scholar 

  9. Stirling J, Griffith M, Dooley JSG, et al.: Zoonoses associated with petting farms and open zoos. Vector-Borne Zoonotic Dis 2007, 8:85–92.

    Article  Google Scholar 

  10. Verma A, Bolton FJ, Fiefield D, et al.: An outbreak of E. coli O157 associated with a swimming pool: an unusual vehicle of transmission. Epidemiol Infect 2007, 135:989–992.

    Article  PubMed  CAS  Google Scholar 

  11. Orskov F, Orskov I, Villar JA: Cattle as a reservoir of verotoxin-producing Escherichia coli O157:H7. Lancet 1987, 2:276.

    Article  PubMed  CAS  Google Scholar 

  12. Paton JC, Paton AW: Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli Infections. Clin Microbiol Rev 1998, 11:450–479.

    PubMed  CAS  Google Scholar 

  13. Goldwater PN, Bettelheim KA: Escherichia coli “O” group serology of a haemolytic uraemic syndrome (HUS) epidemic. Scand J Infect Dis 2000, 32:385–394.

    Article  PubMed  CAS  Google Scholar 

  14. Goldwater PN, Bettelheim KA: New perspectives on the role of Escherichia coli O157:H7 and other enterohemorrhagic E. coli serotypes in human disease. J Med Microbiol 1998, 47:1039–1045.

    Article  PubMed  CAS  Google Scholar 

  15. Tzipori S, Sheoran A, Akiyoshi D, et al.: Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 2004, 17:926–941.

    Article  PubMed  CAS  Google Scholar 

  16. Jacewicz M, Clausen H, Nudelman E, et al.: Pathogenesis of shigella diarrhea. J Exp Med 1986, 163:1391–1404.

    Article  PubMed  CAS  Google Scholar 

  17. Calderwood SB, Auclair F, Donohue-Rolfe A, et al.: Proposed new nomenclature for SLT (VT) family. ASM News 1996, 62:118–119.

    Google Scholar 

  18. Karpac CA, Xiaoning L, Terrell DR, et al.: Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpurahaemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008, 141:696–707.

    Article  PubMed  Google Scholar 

  19. Brandt JR, Fouser LS, Watkins SL, et al.: Escherichia coli O157:H7 associated hemolytic uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994, 125:519–526.

    Article  PubMed  CAS  Google Scholar 

  20. Griffin PM, Ostroff SM, Tauxe RV, et al.: Illnesses associated with E. coli O157:H7 infections: a broad clinical spectrum. Ann Intern Med 1988, 109:705–712.

    PubMed  CAS  Google Scholar 

  21. Griffin PM, Tauxe RV: The epidemiology of infections caused by E. coli O157:H7, other enterohemorrhagic E. coli and associated hemolytic uremic syndrome. Epidemiol Rev 1991, 13:60–98.

    PubMed  CAS  Google Scholar 

  22. Bell BP, Griffin PM, Lozano P, et al.: Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997, 100:E12.

    Article  PubMed  CAS  Google Scholar 

  23. Boldtsetseg T, Chang H, Smith PF, Morse DL: Hemolytic uremic syndrome risk and Escherichia coli O157:H7. Emerg Infect Dis 2005, 11 1955–1957.

    Google Scholar 

  24. Safdar N, Said A, Sangnon RE, Maki GD: Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 Enteritis: a meta-analysis. JAMA 2002, 288:996–1001.

    Article  PubMed  Google Scholar 

  25. Dundas S, Todd WTA, Stewart AI, et al.: The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001, 33:923–931.

    Article  PubMed  CAS  Google Scholar 

  26. Karoonuthaisiri N, Charlermroj R, Uawisetwathana U, et al.: Development of antibody array for simultaneous detection of foodborne pathogens. Biosens Bioelectron 2009, 24:1641–1648.

    Article  PubMed  CAS  Google Scholar 

  27. MacKenzie A, Orrbine E, Hyde L, et al.: Performance of the ImmunoCard STAT! E. coli O157:H7 test for detection of Escherichia coli O157:H7 in stools. J Clin Microbiol 2000, 38:1866–1868.

    PubMed  CAS  Google Scholar 

  28. Lin FYH, Sherman PM, Li D: Development of a novel handheld immunoassay for the detection of enterohemorrhagic Escherichia coli O157-H7. Biomed Microdevices 2004, 6:125–130.

    Article  PubMed  CAS  Google Scholar 

  29. Kamma S, Tang L, Leung K, et al.: A rapid two dot filter assay for the detection of E. coli O157 in water samples. J Immunol Methods 2008, 336:159–165.

    Article  PubMed  CAS  Google Scholar 

  30. Zhao ZJ, Liu XM: Preparation of monoclonal antibody and development of enzyme-linked immunosorbent assay specific for Escherichia coli O157 in foods. Biomed and Environ Sci 2005, 18:254–259.

    CAS  Google Scholar 

  31. Shima K, Kawamura N, Hinenoya A, et al.: Rapid culture-free identification and molecular typing of Shiga toxin-producing Escherichia coli by PCR-RFLP. Microbiol Immunol 2008, 52:310–313.

    Article  PubMed  CAS  Google Scholar 

  32. Banatvala N, Griffin PM, Greene KD, et al.: The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001, 183:1063–1070.

    Article  PubMed  CAS  Google Scholar 

  33. Cimolai N, Morrison BJ, Carter JE: Risk factors for the central nervous system manifestations of gastroenteritisassociated hemolytic-uremic syndrome. Pediatrics 1992, 90:616–621.

    PubMed  CAS  Google Scholar 

  34. Ake JA, Jelacic S, Ciol MA, et al.: Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005, 115 e673–e680.

    Article  PubMed  Google Scholar 

  35. Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga-toxin associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008, 23:1749–1760.

    Article  PubMed  Google Scholar 

  36. Perez N, Spizzirri F, Rahman R, et al.: Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998, 12:101–104.

    Article  PubMed  CAS  Google Scholar 

  37. Afza M, Hawker J, Thurston H, et al.: An outbreak of Escherichia coli O157 gastroenteritis in a care home for the elderly. Epidemiol Infect 2006, 134:1276–1281.

    Article  PubMed  CAS  Google Scholar 

  38. O’Brien SJ, Murdoch PS, Riley AH, et al.: A foodborne outbreak of Vero cytotoxin-producing Escherichia coli O157-H-phage type 8 in hospital. J Hosp Infect 2001, 49:167–172.

    Article  PubMed  Google Scholar 

  39. Werber D, Mason BW, Evans MR, Salmon RL: Preventing household transmission of shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 2008, 46:189–196.

    Article  Google Scholar 

  40. Weightman NC, Kirby PJG: Nosocomial Escherichia coli O157 infection. J Hosp Infect 2000, 44:107–111.

    Article  PubMed  CAS  Google Scholar 

  41. Grif K, Dierich MP, Karch H, Allerberger F: Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998, 17:761–766.

    Article  PubMed  CAS  Google Scholar 

  42. Wong CS, Jelacic S, Habeeb RL, et al.: The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157-H7 infections. N Engl J Med 2000, 342:1930–1936.

    Article  PubMed  CAS  Google Scholar 

  43. Proulx F, Turgeon JP, Delage LG, et al.: Randomized controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992, 121:299–303.

    Article  PubMed  CAS  Google Scholar 

  44. Fukushima H, Hashizume T, Morita Y, et al.: Clinical experiences in Sakai City hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 1999, 41:213–217.

    Article  PubMed  CAS  Google Scholar 

  45. Ochoa TJ, Chen J, Walker CM, et al.: Rifaximin does not induce toxin production of phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2007, 51:2837–2844.

    Article  PubMed  CAS  Google Scholar 

  46. Takahashi M, Taguchi H, Yamaguchi H, et al.: The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol 2004, 41:219–226.

    Article  PubMed  CAS  Google Scholar 

  47. Carey CM, Kostrzynska M, Ojha S, Thompson S: The effect of probiotics and organic acids on shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157:H7. J Microbiol Methods 2008, 73:125–132.

    Article  PubMed  CAS  Google Scholar 

  48. Trachtman H, Cnaan A, Christen E, et al.: Effect of an oral Shiga toxin-binding agent on diarrhea associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003, 290:1337–1344.

    Article  PubMed  CAS  Google Scholar 

  49. Watanabe M, Matsuoka K, Kita E, et al.: Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infection. J Infect Dis 2004, 189:360–368.

    Article  PubMed  CAS  Google Scholar 

  50. Kitov PI, Sadawska JM, Mulvey G, et al.: Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000, 403:669–672.

    Article  PubMed  CAS  Google Scholar 

  51. Nishikawa T, Matsouka K, Kita E, et al.: A therapeutic agent with oriented carbohydrates for treatment of infections by shiga-toxin producing Escherichia coli O157-H7. Proc Nat Acad Sci U S A 2002, 99:7669–7674.

    Article  CAS  Google Scholar 

  52. Nishikawa K, Matsouka K, Watanabe M, et al.: Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 2005, 191:2097–2105.

    Article  PubMed  CAS  Google Scholar 

  53. Mulvey GL, Marcato P, Kitov PI, et al.: Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 2003, 187:640–649.

    Article  PubMed  CAS  Google Scholar 

  54. Orth D, Grif K, Zimmerhackl LB, Wurzner R: Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther 2008, 6:101–108.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mary F. Bavaro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bavaro, M.F. Escherichia coli O157: What every internist and gastroenterologist should know. Curr Gastroenterol Rep 11, 301–306 (2009). https://doi.org/10.1007/s11894-009-0044-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-009-0044-0

Keywords

Navigation